Physician profile
Christopher M Terry
NPI 1881006518
$2,283.01
in general payments reported to CMS, 2019-2025
21 companies · $627 in 2025
The $627 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.48 · 2023: $1,122 · 2024: $489 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664 · Education: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.10 |
| Education | $573.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $406.49 | 2023-2025 | Padcev, Xtandi |
| Janssen Biotech, INC. | $261.07 | 2023-2025 | Erleada, Akeega, Rybrevant |
| Pfizer INC. | $200.43 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $188.36 | 2023-2025 | Imfinzi, Lynparza, Enhertu |
| Amgen INC. | $187.97 | 2022-2023 | Lumakras, Blincyto, Kyprolis |
| Daiichi Sankyo INC. | $171.45 | 2023-2025 | Enhertu, Injectafer |
| Seagen INC. | $161.98 | 2023 | |
| Merck Sharp & Dohme LLC | $135.32 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Myriad Genetic Laboratories, INC. | $82.67 | 2023-2024 | Myrisk, Precisetumor |
| Celgene Corporation | $80.18 | 2022-2025 | Reblozyl, Opdualag |
| Array Biopharma INC | $73.96 | 2023 | Mektovi, Braftovi, Lorbrena |
| Glaxosmithkline, LLC. | $68.06 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $51.41 | 2023-2025 | Venclexta |
| Eisai INC. | $43.70 | 2024-2025 | |
| Taiho Oncology, INC. | $36.50 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $32.80 | 2025 | Xpovio |
| Novartis Pharmaceuticals Corporation | $22.49 | 2025 | |
| Adc Therapeutics America, INC. | $20.40 | 2024 | |
| Cti Biopharma Corp. | $19.77 | 2023 | Vonjo |
| Mirati Therapeutics, INC. | $19.64 | 2023 | Krazati |
| Sun Pharmaceutical Industries INC. | $18.36 | 2023 | Yonsa, Odomzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.